1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,454 | 0,500 | 10.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| JW THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | China Reviews JW Therapeutics' Plan to Use Own Lentiviral Vector to Cut Cost of CAR-T Cancer Drug | 1 | Yicai Global | ||
| Do | JW THERAP-B (02126): VOLUNTARY ANNOUNCEMENT - RESEARCH AND DEVELOPMENT UPDATE - NATIONAL MEDICAL PRODUCTS ADMINISTRATION OFFICIALLY ACCEPTED THE POST-MARKETING ... | - | HKEx | ||
| 30.09. | JW THERAP-B (02126): DELAY IN DESPATCH OF CIRCULAR | - | HKEx | ||
| 25.09. | JW THERAP-B (02126): 2025 INTERIM REPORT | - | HKEx | ||
| 16.09. | JW THERAP-B (02126): GRANT OF SHARE OPTIONS | 2 | HKEx | ||
| 27.08. | JW THERAP-B (02126): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND CHANGE IN USE OF NET PROCEEDS FROM LISTING | - | HKEx | ||
| 15.08. | JW THERAP-B (02126): NOTICE OF BOARD MEETING | 1 | HKEx | ||
| 26.06. | JW THERAP-B (02126): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2025 | - | HKEx | ||
| 03.06. | JW THERAP-B (02126): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON JUNE 3, 2025 | 2 | HKEx | ||
| 28.05. | JW THERAP-B (02126): VOLUNTARY ANNOUNCEMENT - RESEARCH AND DEVELOPMENT UPDATE NMPA ACCEPTANCE OF THE SUPPLEMENTAL BIOLOGICAL LICENSE APPLICATION FOR CARTEYVA ... | - | HKEx | ||
| 15.05. | JW THERAP-B (02126): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON JUNE 3, 2025 | - | HKEx | ||
| 15.05. | JW THERAP-B (02126): NOTICE OF EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 15.05. | JW THERAP-B (02126): CONNECTED TRANSACTION IN RELATION TO LICENSE AGREEMENT | - | HKEx | ||
| 14.05. | JW THERAP-B (02126): CLOSURE OF REGISTER OF MEMBERS | - | HKEx | ||
| 08.05. | JW THERAP-B (02126): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON JUNE 26, 2025 | - | HKEx | ||
| 08.05. | JW THERAP-B (02126): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 08.05. | JW THERAP-B (02126): PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES, TRANSFER SHARES OUT OF TREASURY AND REPURCHASE SHARES AND RE-ELECTION OF DIRECTORS ... | 3 | HKEx | ||
| 28.04. | JW THERAP-B (02126): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| 28.04. | JW THERAP-B (02126): 2024 ANNUAL REPORT | 1 | HKEx | ||
| 22.04. | JW THERAP-B (02126): CONNECTED TRANSACTION IN RELATION TO THE LICENSE AGREEMENT AND FURTHER INFORMATION RELATING TO THE MATERIAL TRANSFER AGREEMENT | 2 | HKEx |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,470 | -1,56 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 20,050 | -3,19 % | Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 | ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere... ► Artikel lesen | |
| EVOTEC | 6,698 | -0,86 % | Evotec Aktie: Strohfeuer oder klappt es diesmal? | Die Evotec Aktie zeigt Stärke - aber diesmal auch für eine längere Zeit? Seit dem 26. September hat sich die TecDAX-notierte Biotech-Aktie von 5,882 Euro um mehr als einen Euro verteuert. Am gestrigen... ► Artikel lesen | |
| 89BIO | 14,800 | -0,34 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| BIONTECH | 87,95 | +0,11 % | BioNTech Aktie zeigt Stärke: Es wird spannend! | Seit dem letzten 4investors.de-Chartcheck zur BioNTech Aktie hat sich einiges getan. Der Aktienkurs des Mainzer Biotech-Konzerns ist an der NASDAQ um rund 9 Dollar gestiegen, hat die 20- und 50-Tage-Linie... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,305 | -10,24 % | Recursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI Conference | ||
| BEAM THERAPEUTICS | 26,340 | -5,49 % | Jefferies stuft Beam Therapeutics auf "Buy": Kommende Katalysatoren im Fokus | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 10,290 | +9,70 % | Oppenheimer senkt Kursziel für Moonlake Immunotherapeutics nach durchwachsenen Studienergebnissen | ||
| MINERALYS THERAPEUTICS | 42,170 | +7,06 % | Mineralys Therapeutics: Aktie erreicht Rekordhoch von 41,11 USD | ||
| ARCELLX | 86,80 | -1,84 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| LENZ THERAPEUTICS | 38,740 | -16,24 % | Piper Sandler raises LENZ Therapeutics stock price target to $67 on VIZZ launch | ||
| APOGEE THERAPEUTICS | 52,45 | -1,43 % | Apogee Therapeutics schließt Kapitalerhöhung über 345 Millionen US-Dollar ab | ||
| BICARA THERAPEUTICS | 17,780 | -2,58 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Updated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R/M HNSCC Data from additional Phase 1/1b expansion cohorts evaluating... ► Artikel lesen | |
| COGENT BIOSCIENCES | 16,250 | +0,37 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,320 | -5,87 % | UBS bestätigt Kaufempfehlung für Summit Therapeutics vor ESMO-Daten |
JW CAYMAN THERAPEUTICS CO LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,88 % bei einem Aktienkurs von 0,456 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JW CAYMAN THERAPEUTICS CO LTD finden Sie auf Wallstreet Online.